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Associations between habitual flavonoid intake and hospital 
admissions for atherosclerotic cardiovascular disease: 
a prospective cohort study
Frederik Dalgaard*, Nicola P Bondonno*, Kevin Murray, Catherine P Bondonno, Joshua R Lewis, Kevin D Croft, Cecilie Kyrø, Gunnar Gislason, 
Augustin Scalbert, Aedin Cassidy, Anne Tjønneland, Kim Overvad, Jonathan M Hodgson
Summary
Background Flavonoids, compounds found in plant-based foods and beverages, might ameliorate vascular damage 
and atherosclerosis. Therefore, our aim was to assess the association between flavonoid intake and hospital admissions 
due to atherosclerotic cardiovascular disease.
Methods In this prospective cohort study, participants from the Danish Diet, Cancer, and Health Study were cross-
linked with Danish nationwide registries. Eligible participants were aged 50–65 years, had no previous history of 
atherosclerotic cardiovascular disease, and had completed a food-frequency questionnaire at baseline. We examined 
associations between flavonoid intake (calculated from food-frequency questionnaires with use of the Phenol-Explorer 
database) and hospital admissions for atherosclerotic cardiovascular disease, ischaemic heart disease, ischaemic 
stroke, or peripheral arterial disease. We obtained hazard ratios (HRs) using restricted cubic splines based on Cox 
proportional hazards models.
Findings Of the participants recruited to the Danish Diet, Cancer, and Health study between 1993 and 1997, our study 
population was comprised of 53 552 participants, with a median follow-up of 21 years (IQR 15–22). During follow-up, 
8773 participants were admitted to hospital for atherosclerotic cardiovascular disease. We observed non-linear 
associations between flavonoid intake and hospital admissions, plateauing at total flavonoid intakes of approximately 
1000 mg per day. Compared with an intake of 175 mg per day, an intake of 1000 mg per day was associated with a 14% 
lower risk of atherosclerotic cardiovascular disease (HR 0·86, 95% CI 0·81–0·91). For disease subtypes, we observed 
a 9% lower risk of ischaemic heart disease (0·91, 0·85–0·98), a non-significant 9% lower risk of ischaemic stroke 
(0·91, 0·82–1·01), and a 32% lower risk of peripheral artery disease (0·68, 0·60–0·78). The overall associations were 
stronger in smokers than in non-smokers, as well as stronger in consumers of high (>20 g per day) quantities of 
alcohol than in those consuming low-to-moderate (≤20 g per day) quantities.
Interpretation Our results suggest that ensuring an adequate consumption of flavonoid-rich foods, particularly in 
subpopulations at risk of atherosclerosis such as smokers and consumers of high quantities of alcohol might mitigate 
some of the risk of atherosclerotic cardiovascular disease. More studies are needed to support and validate these data.
Funding Danish Cancer Society.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The exploration of evidence-based approaches to prevent 
cardiovascular disease is crucial to combat the world’s 
leading cause of death. Findings from the 2015 he Global 
Burden of Diseases, Injuries, and Risk Factors Study1 
indicate that, in Denmark, approximately 44% of deaths 
due to cardiovascular disease are associated with dietary 
risk factors. Globally, this proportion is closer to 56%, 
with the primary dietary risk factor associated with the 
development of cardiovascular disease being a low intake 
of fruits.2
One hypothesis to explain the cardioprotective effects 
of fruits and many vegetables is that these benefits are 
partly due to flavonoids, a group of bioactive compounds.3 
Flavonoids are also found in other plant-based foods and 
beverages such as tea, cocoa, and red wine and are 
categorised into subclasses on the basis of their chemical 
structure.4 These structural variations yield differences in 
bioavailability and biological activity, making the 
individual assessment of the effects of these subclasses 
particularly informative.5 However, flavonoid compounds 
from different subclasses are catabolised by the gut 
microbiome into smaller phenolic and aromatic acids 
that are common to several subclasses.6 Therefore, 
assessing total flavonoid intake is also of value.
Small-scale, short-term intervention studies have 
explored the effects of flavonoids on validated measures of 
vascular health. These studies have shown that flavonoid-
rich foods and specific flavonoid compounds can have a 
positive effect on surrogate markers of cardiovascular 
health such as blood pressure, vascular function, arterial 
stiffness, blood lipids, and inflam mation.7 Evidence 
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suggests that flavonoids might ameliorate the initiation 
and progression of atherosclerosis, the leading cause of 
cardio vascular disease, through regulation of inflam-
mation and redox processes.8 Large long-term epide-
miological studies are now needed to examine associations 
between flavonoid intake and atherosclerotic cardio-
vascular disease, partic ularly in subpopulations prone to 
atherosclerosis.9
Therefore, the primary aim of our study was to 
investigate the association of total flavonoid intake and 
intake by flavonoid subclass and of major flavonoid 
compounds with incident atherosclerotic cardiovascular 
disease in the Danish Diet, Cancer, and Health cohort. 
Secondary aims were to assess whether these associ-
ations differed by sex, smoking status, alcohol consump-
tion, body-mass index (BMI), and presence of prevalent 
diabetes.
Methods
Study design and population
For our prospective cohort study, we used the Danish 
Diet, Cancer, and Health study, an associated cohort of 
the European Prospective Investigation into Nutrition 
and Cancer, which recruited residents of the greater 
areas of Copenhagen and Aarhus.10 Eligible participants 
for this study were aged 50–65 years and had completed a 
food-frequency questionnaire at baseline in the Danish 
Diet, Cancer, and Health study. Using the Danish civil 
registration system, we linked participants to nationwide 
registers on the individual level. The following databases 
were cross-linked to the cohort: the Civil Registration 
System, the Integrated Database for Labor Market 
Research, and the Danish National Patient Register 
(DNPR). The DNPR holds information on date of 
hospital admissions in Denmark since 1978 and date of 
discharge with one primary diagnosis and one or more 
secondary diagnoses defined by the International 
Classification of Diseases (ICD), the 8th revision (ICD-8) 
until 1993 and the 10th revision (ICD-10) from 
1994 onwards (appendix p 1).11 Participants were excluded 
if they had any prevalent atherosclerotic cardiovascular 
disease, which included self-reported myocardial infar-
ction, previous diagnosis of ischaemic heart disease, self-
reported ischaemic stroke, previous diagnosis of 
ischaemic stroke, or previous diag nosis of peripheral 
artery disease. Furthermore, partici pants were excluded 
if they had missing covariates, were extreme outliers 
(appendix p 7), or had implaus ible energy intakes 
(<2092 kJ per day [<500 kcal per day] or >20 920 kJ per 
day [>5000 kcal per day]).
In Denmark, register studies do not require approval 
from an ethics committee. This study was approved by 
the Danish Data Protection Agency.
Procedures
Exposures in our study were intakes of total flavonoids, 
and flavonoid subclasses and individual flavonoid 
compounds with mean intakes greater than 5 mg per 
day. These intakes were estimated from dietary data, 
collected at baseline by use of a validated 192-item food-
frequency questionnaire mailed out to participants 
before their visit to one of the two study centres.12 
Full details of the Phenol-Explorer calculations have 
been published previously.13,14 Phenol-Explorer is a 
comprehensive database on the flavonoid and, more 
broadly, the polyphenol content of more than 400 foods. 
Research in context
Evidence before this study
We searched Google Scholar and PubMed for studies in any 
language published up to and including Jan 31, 2019 (with no 
earliest date specified), analysing the association between 
flavonoid intake and cardiovascular disease. We used the search 
terms “flavonoid”, “polyphenol”, “cardiovascular disease”, “heart 
disease”, and “stroke”. In a 2015 meta-analysis of 15 prospective 
cohort studies, individuals with the highest flavonoid intakes 
had a 15% lower relative risk of coronary heart disease compared 
with that of individuals with the lowest intakes. Although 
evidence suggests that flavonoids afford protection against 
atherosclerosis, to our knowledge, no studies have investigated 
the association between flavonoid intake and all cardiovascular 
diseases with an atherosclerotic cause. Additionally, although 
hypothesised, previous studies have been underpowered to 
detect differing associations in at-risk subpopulations.
Added value of this study
Our study provides evidence of non-linear associations 
between total flavonoid intake and atherosclerotic 
cardiovascular disease, which plateau at intakes of 
approximately 1000 mg per day. To our knowledge, this is the 
first study to show that for smokers and consumers of high 
quantities of alcohol, the association between flavonoid intake 
and atherosclerotic cardiovascular disease was stronger and 
additional benefit was seen for higher intakes compared with 
that for non-smokers and individuals who consumed 
low-to-moderate amounts of alcohol. Furthermore, this is the 
first study to suggest that cardiovascular protective effects of 
flavonoids occur primarily in the peripheral arteries.
Implications of all the available evidence
These findings highlight a potential strategy to improve 
population health with dietary recommendations ensuring the 
adequate consumption of flavonoid-rich foods. Our findings 
suggest that flavonoids might have an even more crucial role in 
the prevention of atherosclerotic cardiovascular disease in 
high-risk populations.
See Online for appendix
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Total population 
(n=53 552)
Total flavonoid intake
Quintile 1 (n=10 711) Quintile 2 (n=10 710) Quintile 3 (n=10 710) Quintile 4 (n=10 710) Quintile 5 (n=10 711)
Total flavonoid intake (mg per day) 499 (290–808) 175 (129–215) 323 (290–360) 498 (445–552) 730 (663–808) 1205 (1028–1437)
Sex
Men 24 952 (46·6%) 6069 (56·7%) 5392 (50·3%) 4999 (46·7%) 4644 (43·4%) 3848 (35·9%)
Women 28 600 (53·4%) 4642 (43·3%) 5318 (49·7%) 5711 (53·3%) 6066 (56·6%) 6863 (64·1%)
Age (years) 56 (52–60) 55 (52–60) 56 (52–60) 56 (52–60) 56 (52–60) 55 (52–59)
BMI (kg/m²) 25·5 (23·2–28·1) 26·1 (23·7–28·8) 25·8 (23·6–28·4) 25·5 (23·3–28·2) 25·3 (23·1–27·8) 24·8 (22·7–27·3)
MET score 56·5 (37·0–84·8) 51·0 (32·5–78·0) 55·5 (36·5–84·0) 57·3 (38·5–84·7) 58·5 (38·8–87·0) 60·0 (40·0–88·5)
Smoking status
Never 19 258 (36·0%) 2724 (25·4%) 3684 (34·4%) 3922 (36·6%) 4322 (40·4%) 4606 (43·0%)
Former 15 205 (28·4%) 2524 (23·6%) 2867 (26·8%) 3059 (28·6%) 3405 (31·8%) 3350 (31·3%)
Current 19 089 (35·6%) 5463 (51·0%) 4159 (38·8%) 3729 (34·8%) 2983 (27·9%) 2755 (25·7%)
Education (years)
≤7 17 293 (32·3%) 4832 (45·1%) 3990 (37·3%) 3365 (31·4%) 2838 (26·5%) 2268 (21·2%)
8–10 24 836 (46·4%) 4718 (44·0%) 5083 (47·5%) 5158 (48·2%) 5083 (47·5%) 4794 (44·8%)
≥11 11 400 (21·3%) 1156 (10·8%) 1634 (15·3%) 2183 (20·4%) 2784 (26·0%) 3643 (34·0%)
Mean household income (DKK per year)
≤394 700 13 044 (24·4%) 3122 (29·1%) 2569 (24·0%) 2550 (23·8%) 2422 (22·6%) 2381 (22·2%)
394 701–570 930 13 289 (24·8%) 3095 (28·9%) 2848 (26·6%) 2577 (24·1%) 2467 (23·0%) 2302 (21·5%)
570 931–758 297 13 500 (25·2%) 2827 (26·4%) 2924 (27·3%) 2765 (25·8%) 2520 (23·5%) 2464 (23·0%)
>758 297 13 719 (25·6%) 1667 (15·6%) 2369 (22·1%) 2818 (26·3%) 3301 (30·8%) 3564 (33·3%)
Hypertensive 8201 (15·3%) 1597 (14·9%) 1694 (15·8%) 1662 (15·5%) 1642 (15·3%) 1606 (15·0%)
Hypercholesterolaemic 3397 (6·3%) 696 (6·5%) 676 (6·3%) 703 (6·6%) 707 (6·6%) 615 (5·7%)
Comorbidities
Diabetes 1000 (1·9%) 240 (2·2%) 189 (1·8%) 202 (1·9%) 180 (1·7%) 189 (1·8%)
Heart failure 91 (0·2%) 16 (0·1%) 23 (0·2%) 18 (0·2%) 17 (0·2%) 17 (0·2%)
Atrial fibrillation 209 (0·4%) 37 (0·3%) 45 (0·4%) 43 (0·4%) 36 (0·3%) 48 (0·4%)
COPD 751 (1·4%) 190 (1·8%) 160 (1·5%) 142 (1·3%) 139 (1·3%) 120 (1·1%)
CKD 178 (0·3%) 35 (0·3%) 28 (0·3%) 39 (0·4%) 40 (0·4%) 36 (0·3%)
Cancer 227 (0·4%) 48 (0·4%) 40 (0·4%) 55 (0·5%) 32 (0·3%) 52 (0·5%)
Medication use
Insulin 331 (0·6%) 70 (0·7%) 57 (0·5%) 71 (0·7%) 69 (0·6%) 64 (0·6%)
Antihypertensive 6122 (11·4%) 1181 (11·0%) 1287 (12·0%) 1242 (11·6%) 1212 (11·3%) 1200 (11·2%)
Statin 624 (1·2%) 133 (1·2%) 138 (1·3%) 129 (1·2%) 122 (1·1%) 102 (1·0%)
HRT
Never 15 553 (29·0%) 2560 (23·9%) 2976 (27·8%) 3163 (29·5%) 3204 (29·9%) 3650 (34·1%)
Current 8610 (16·1%) 1283 (12·0%) 1513 (14·1%) 1664 (15·5%) 1948 (18·2%) 2202 (20·6%)
Former 4406 (8·2%) 790 (7·4%) 825 (7·7%) 875 (8·2%) 910 (8·5%) 1006 (9·4%)
NSAID 17 081 (31·9%) 3268 (30·5%) 3312 (30·9%) 3444 (32·2%) 3433 (32·1%) 3624 (33·8%)
Aspirin 6484 (12·1%) 1233 (11·5%) 1254 (11·7%) 1318 (12·3%) 1280 (12·0%) 1399 (13·1%)
Dietary characteristics (g per day)
Energy (kj) 9498 (7852–11 365) 8600 (7025–10 396) 9249 (7715–11 009) 9742 (8126–11 581) 9922 (8315–11 807) 9920 (8255–11 875)
Total fish intake 38 (25–55) 33 (22–48) 38 (25–54) 39 (27–57) 41 (28–59) 39 (27–56)
Red meat intake 78 (56–107) 80 (57–108) 81 (59–109) 80 (58–110) 78 (56–107) 72 (52–99)
Processed meat intake 24 (14–40) 28 (17–45) 26 (15–42) 25 (14–40) 23 (14–37) 20 (11–34)
Dietary fibre intake 20 (16–25) 17 (13–20) 19 (16–23) 21 (17–25) 22 (18–27) 23 (19–29)
Fruit intake 172 (95–282) 88 (45–142) 162 (98–239) 193 (114–301) 225 (140–360) 240 (141–390)
Vegetable intake 162 (105–231) 115 (72–171) 150 (100–212) 168 (114–236) 185 (127–254) 196 (136–272)
Alcohol intake 13 (6–31) 11 (3–23) 13 (6–25) 15 (6–33) 14 (7–32) 13 (6–32)
Data are median (IQR) or n (%), unless otherwise specified. BMI=body-mass index. MET=metabolic equivalent. DKK=Danish Krone. COPD=common obstructive pulmonary disease. CKD=chronic kidney disease. 
HRT=hormone replacement therapy. NSAID=non-steroidal anti-inflammatory drug.
Table 1: Baseline characteristics
Articles
e453 www.thelancet.com/planetary-health   Vol 3   November 2019
Significant correlations have been found between 24-h 
urine concentrations of 12 flavonoids and intake of their 
main food sources in 475 participants of the EPIC study.15 
In our study, we estimated the intakes of 219 different 
flavonoids. These were grouped into nine classes 
according to their chemical structure (flavonols, flavones, 
flavanols [flavanol monomers and flavanol oligomers 
and polymers], flavanones, isoflavones, anthocyanins, 
chalcones, dihydrochalcones, and dihydro flavonols) 
by summing the intakes of each individual flavonoid 
compound within their respective flavonoid class. We 
calculated total flavonoid intake by summing each of the 
flavonoid compounds.
We obtained information on sex, age, education, 
smoking habits, alcohol consumption, and daily activity 
from self-administered questionnaires completed by 
participants at Danish Diet, Cancer, and Health study 
enrolment. Dietary data were obtained from the semi-
quantitative food frequency questionnaire. Anthro-
pometric measures and total blood cholesterol were 
taken at the Danish Diet, Cancer, and Health study 
centres. We defined average annual income as household 
income after taxation and interest, for the value of the 
Danish currency in 2015, and we used the value over 
5 years as a proxy for socioeconomic status. We used 
ICD-8 and ICD-10 codes for diagnosis of chronic kidney 
disease, chronic obstructive pulmonary disease, heart 
failure, atrial fibrillation, and cancers. For hyper tension 
and diabetes, only self-reported data were used because 
of the low validity of ICD codes in DNPR.16
Outcomes
The primary outcome was a combined endpoint of 
first-time hospital admission for atherosclerotic cardio-
vascular disease. Atherosclerotic cardiovascular disease 
was defined as hospital admission with a primary or 
secondary diagnosis code for ischaemic heart disease, 
ischaemic stroke, or peripheral artery disease. Second ary 
outcomes were discrete hospital admissions for 
ischaemic heart disease, ischaemic stroke, and peripheral 
artery disease. These ICD codes have previously been 
validated in the DNPR.16 Diagnoses of unstable angina or 
transient ischaemic attack were not included because 
these do not have validity and specificity in the DNPR.
To verify the registry-based outcomes, we re-examined 
associations using only medically reviewed and validated 
cases (appendix p 1).
Statistical analysis
Participants were followed up for a maximum of 
23 years from the date of enrolment until death from 
any cause, emigration, hospital admission for 
atherosclerotic cardiovascular disease (first hospital 
admission for the combined endpoint), or end of follow-
up (August, 2017), whichever came first. We computed 
Nelson-Aalen plots of cumulative incidence for 
atherosclerotic cardiovascular disease with a competing 
risk of death and by quintile of total flavonoid intake. 
We used restricted cubic splines with four knots (located 
at the fifth, 35th, 65th, and 95th percentiles) to 
investigate non-linear relationships between flavonoid 
intakes and all outcomes, with hazard ratios (HRs) 
derived from Cox proportional hazards models. We 
plotted HRs with 95% CIs for each unit of the exposure 
using the median intake in quintile 1 as the reference. 
Individuals with intakes greater than 4 SD above the 
mean were excluded from the spline analysis. The test 
of non-linearity used analysis of variance to compare the 
model only with the linear term to the model that 
included both linear and non-linear terms. We obtained 
HRs and 95% CIs for the median intakes in each 
quintile of the exposure variables from the splines. Cox 
proportional hazards assumptions were tested using 
log-log plots of the survival function versus time and 
assessed for parallel appearance, with no violation 
found. Because our aim was to obtain relative estimates 
for risk factors, all deaths were cen sored rather 
than treated as a competing risk. We used six models 
of adjustment: minimally adjusted (model 1), multi-
variable-adjusted (model 2), multivariable-adjusted 
including energy (model 3), multivariable-adjusted inc-
luding covariates on the causal pathway (model 4), 
multivariable-adjusted including potential dietary 
Figure 1: Association between total flavonoid intake and hospital admissions 
for atherosclerotic cardiovascular disease
Cubic spline curves describe the association between total flavonoid intake 
(mg per day) and hospital admissions for both total atherosclerotic cardiovascular 
disease and disease subtypes. Hazard ratios are based on Cox proportional hazards 
models adjusted for age, sex, body-mass index, smoking status, socioeconomic 
status (income), physical activity, and alcohol intake (model 2), and are 
comparing the specific level of flavonoid intake (horizontal axis) with the median 
intake for participants in the lowest intake quintile (175 mg per day). 
IHD=ischaemic heart disease. PAD=peripheral artery disease.
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confounders (model 5), and multivariable-adjusted 
including potential dietary confounders that are also a 
source of flavonoids (model 6; appendix p 1). Covariates 
were chosen a priori according to the best of our 
knowledge of potential confounders of flavonoid intake 
and cardio vascular disease. We assumed absolute 
flavonoid intake to be more relevant than energy-
adjusted values; therefore we did not include total 
energy intake as a covariate in the main models. 
However, energy intake was added to model 2 in a 
sensitivity analysis (model 3). Analyses were stratified 
by sex, BMI, baseline diabetes status, smoking status, 
and alcohol intake to test for potential effect 
modification. When stratifying by alcohol intake, we 
excluded all participants with an alcohol intake of 
zero (1180 participants) and when stratifying by BMI, 
we excluded those with a BMI lower than 18·5 
(426 participants), because these were not our subgroups 
Quintile 1 (n=10 711) Quintile 2 (n=10 710) Quintile 3 (n=10 710) Quintile 4 (n=10 710) Quintile 5 (n=10 711)
Total flavonoids
Number of events 2199 1844 1749 1573 1408
Intake (mg per day)* 175 (6–253) 323 (253–397) 498 (397–605) 730 (605–912) 1205 (912–3552)
HR (95% CI)
Model 1 1 (ref) 0·84 (0·81–0·87) 0·74 (0·71–0·78) 0·70 (0·66–0·73) 0·66 (0·63–0·70)
Model 2 1 (ref) 0·94 (0·90–0·97) 0·89 (0·85–0·94) 0·87 (0·82–0·92) 0·85 (0·81–0·91)
Model 5 1 (ref) 0·95 (0·91–0·99) 0·91 (0·87–0·96) 0·90 (0·85–0·95) 0·89 (0·84–0·95)
Flavonols
Number of events 2257 2581 2285 2194 2133
Intake (mg per day)* 15 (0–21) 26 (21–32) 39 (32–50) 66 (50–83) 116 (83–251)
HR (95% CI)
Model 1 1 (ref) 0·83 (0·80–0·86) 0·73 (0·69–0·76) 0·67 (0·63–0·70) 0·65 (0·61–0·69)
Model 2 1 (ref) 0·92 (0·88–0·95) 0·86 (0·82–0·91) 0·85 (0·80–0·89) 0·84 (0·79–0·89)
Model 5 1 (ref) 0·92 (0·89–0·96) 0·88 (0·83–0·93) 0·87 (0·82–0·92) 0·87 (0·82–0·92)
Flavanol monomers
Number of events 2279 1826 1722 1546 1400
Intake (mg per day)* 14 (0–21) 30 (21–46) 68 (46–116) 261 (116–282) 474 (282–916)
HR (95% CI)
Model 1 1 (ref) 0·90 (0·88–0·92) 0·75 (0·71–0·80) 0·68 (0·64–0·72) 0·68 (0·64–0·72)
Model 2 1 (ref) 0·95 (0·93–0·97) 0·88 (0·83–0·93) 0·86 (0·82–0·92) 0·87 (0·82–0·92)
Model 5 1 (ref) 0·96 (0·94–0·98) 0·90 (0·85–0·95) 0·89 (0·84–0·94) 0·90 (0·84–0·95)
Flavanol oligo+polymers
Number of events 2192 1934 1631 1578 1438
Intake (mg per day)* 93 (0–137) 180 (137–218) 257 (218–304) 361 (304–435) 538 (435–2254)
HR (95% CI)
Model 1 1 (ref) 0·82 (0·78–0·85) 0·73 (0·70–0·77) 0·68 (0·64–0·71) 0·65 (0·62–0·69)
Model 2 1 (ref) 0·93 (0·89–0·97) 0·87 (0·83–0·92) 0·83 (0·78–0·88) 0·82 (0·78–0·87)
Model 5 1 (ref) 0·94 (0·90–0·98) 0·89 (0·85–0·94) 0·86 (0·81–0·90) 0·86 (0·81–0·91)
Anthocyanins
Number of events 2043 1660 1597 1735 1738
Intake (mg per day)* 5 (0–9) 13 (9–17) 20 (17–24) 35 (24–53) 70 (53–397)
HR (95% CI)
Model 1 1 (ref) 0·77 (0·73–0·80) 0·71 (0·67–0·75) 0·75 (0·71–0·79) 0·83 (0·78–0·88)
Model 2 1 (ref) 0·91 (0·87–0·96) 0·89 (0·84–0·95) 0·94 (0·88–0·99) 0·98 (0·92–1·05)
Model 5 1 (ref) 0·92 (0·88–0·97) 0·91 (0·85–0·97) 0·96 (0·90–1·02) 1·01 (0·94–1·07)
Flavanones
Number of events 1939 1734 1761 1591 1748
Intake (mg per day)* 3 (0–6) 9 (6–13) 18 (13–26) 32 (26–50) 70 (50–364)
HR (95% CI)
Model 1 1 (ref) 0·92 (0·88–0·96) 0·85 (0·80–0·91) 0·83 (0·79–0·88) 0·86 (0·81–0·91)
Model 2 1 (ref) 0·98 (0·94–1·02) 0·96 (0·90–1·02) 0·93 (0·88–0·99) 0·95 (0·90–1·01)
Model 5 1 (ref) 0·99 (0·95–1·03) 0·97 (0·91–1·03) 0·95 (0·89–1·00) 0·96 (0·91–1·02)
(Table 2 continues on  next page)
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of interest. We chose stratification cutoff points of 20 g 
pure alcohol per day (two standard drinks) and a BMI of 
30 kg/m², because the risk of mortality is higher beyond 
these levels.17 We did analyses using STATA/IC, version 
14.2, and R statistics. Statistical significance was set at 
p≤0·05 (two-tailed) for all tests.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. FD, NPB, and GG had full access to all the 
data in the study. All authors had final responsibility for 
the decision to submit for publication.
Results
Between Nov 24, 1993, and May 28, 1997, the Danish 
Diet, Cancer, and Health study recruited 
57 053 participants. Of these, 56 468 completed a food-
frequency questionnaire at baseline. 2916 participants 
did not meet the inclusion criteria, resulting in a study 
population of 53 552 participants (appendix p 2).
Our study cohort had a median age of 56 years 
(IQR 52–60) at entry and a median follow-up of 21 years 
(15–22). During a total of 939 031 person-years of follow-
up, 8773 individuals were admitted to hospital for any 
atherosclerotic cardiovascular disease, 5323 for ischaemic 
heart disease, 2920 for ischaemic stroke, and 1867 for 
peripheral artery disease. Furthermore, 9522 participants 
died from any cause without having been admitted to 
hospital for an atherosclerotic cardiovascular disease. 
The cumulative incidence of hospital admissions for 
atherosclerotic cardiovascular disease and death without 
admission for atherosclerotic cardiovascular disease are 
shown in the appendix (p 3).
Participants in the highest quintile of flavonoid intake 
were more likely to be women and tended to have a lower 
BMI; be more physically active; have never smoked; have 
a higher education degree; have a higher income; eat 
more fish, fibre, vegetables, and fruit; and eat less red 
and processed meat than participants in the lowest 
quintile of flavonoid intake (table 1).
Cumulative incidences of atherosclerotic cardiovascular 
disease, ischaemic heart disease, ischaemic stroke, and 
peripheral artery disease for each quintile of total 
flavonoid intake are shown in the appendix (p 3). The 
inverse association between total flavonoid intake and 
total athero sclerotic cardiovascular disease was non-
linear (p<0·001), and the restricted cubic splines showed 
a threshold of association at approximately 1000 mg per 
day (figure 1). Compared with a total flavonoid intake of 
Quintile 1 (n=10 711) Quintile 2 (n=10 710) Quintile 3 (n=10 710) Quintile 4 (n=10 710) Quintile 5 (n=10 711)
(Continued from previous page)
Flavones
Number of events 1941 1809 1672 1644 1707
Intake (mg per day)* 2 (0–3) 4 (3–5) 5 (5–6) 7 (6–9) 11 (9–51)
HR (95% CI)
Model 1 1 (ref) 0·84 (0·79–0·88) 0·80 (0·75–0·84) 0·77 (0·73–0·81) 0·79 (0·75–0·84)
Model 2 1 (ref) 0·93 (0·88–0·98) 0·91 (0·86–0·96) 0·89 (0·84–0·94) 0·90 (0·85–0·96)
Model 5 1 (ref) 0·94 (0·89–0·99) 0·93 (0·87–0·98) 0·91 (0·86–0·97) 0·94 (0·88–1·00)
Hazard ratios (HR; 95% CI) for hospital admissions for atherosclerotic cardiovascular disease during 23 years of follow-up, obtained from restricted cubic splines based on Cox 
proportional hazards models. Model 1 adjusted for age and sex; model 2 adjusted for age, sex, body-mass index, smoking status, physical activity, alcohol intake, and social 
economic status (income); model 5 adjusted for all covariates in model 2 plus intakes of fish, red meat, processed food, polyunsaturated fatty acids, monounsaturated fatty 
acids, and saturated fatty acids. *Median (range).
Table 2: Hospital admissions for atherosclerotic cardiovascular disease by quintiles of flavonoid intake
Figure 2: Association between flavonoid subclass intakes (mg per day) and total hospital admissions for 
atherosclerotic cardiovascular disease
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, body-mass index, smoking status, 
social economic status (income), physical activity, and alcohol intake (model 2), and are comparing the specific level 
of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile.
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175 mg per day (median intake in quintile 1), an intake of 
1000 mg per day was associated with a 14% lower risk of 
atherosclerotic cardiovascular disease (HR 0·86, 95% CI 
0·81–0·91). For atherosclerotic cardiovascular disease 
subtypes, a total flavonoid intake of 1000 mg per day was 
associated with a 9% lower risk of ischaemic heart 
disease (0·91, 0·85–0·98), a non-significant 9% lower 
risk of ischaemic stroke (0·91, 0·82–1·01), and a 
32% lower risk of peripheral artery disease (0·68, 
0·60–0·78) compared with a 175 mg per day intake 
(model 2). For all flavonoid subclasses, after multi-
variable adjustments (models 2 and 3), participants in 
quintiles 2–5 had a lower risk of atherosclerotic 
cardiovascular disease than that of participants in 
quintile 1 (table 2). HRs for alternative models of 
adjustment (models 4 and 6) did not differ substantively 
from HRs from model 2 (appendix p 4). We observed 
thresholds of benefit at varying levels of intake for each 
flavonoid subclass (figure 2).
Intakes of kaempferol, quercetin, epicatechin, procy-
anidin dimers, and apigenin greater than those in 
quintile 1 were associated with a significantly lower risk 
of hospital admissions for atherosclerotic cardiovascular 
disease after adjustment for potential lifestyle (model 2) 
and dietary confounders (model 5), with no further 
differ ences in HRs observed beyond quintile 4 (figure 3, 
appendix pp 5–6). The observed association was more 
linear for malvidin and procyanidin trimers than for 
other compounds. The HRs were 0·76 (95% CI 
0·70–0·83) for malvidin and 0·79 (0·74–0·84) for 
procyanidin trimers in quintile 5 versus quintile 1 after 
adjustment for potential lifestyle confounders (model 2).
The association between flavonoid intake and athero-
sclerotic cardiovascular disease differed according to 
smoking status, alcohol intake, and BMI, but not by 
prevalence of diabetes or by sex for intakes lower than 
1000 mg per day.
Because we observed no difference in the association 
between flavonoid intake and hospital admissions for 
atherosclerotic cardiovascular disease for never smokers 
compared with that for former smokers, these subgroups 
were combined (data not shown). The inverse associ-
ation between total flavonoid intake and atherosclerotic 
cardiovascular disease was stronger in smokers than 
in non-smokers and stronger in participants who 
consumed more than 20 g per day of alcohol than in those 
who consumed 20 g per day or less of alcohol (figure 4). A 
total flavonoid intake of 1000 mg per day was associated 
with a 22% lower risk of atherosclerotic cardiovascular 
disease in smokers (HR 0·78, 95% CI 0·72–0·85), a 
non-significant 5% lower risk in non-smokers (0·95, 
0·87–1·03), a 21% lower risk in high alcohol consumers 
(0·79, 0·71–0·87), and an 11% lower risk in low-to-
moderate alcohol consumers (0·89, 0·82–0·95; model 2). 
Comparing participants in quintile 5 with those in 
quintile 1 of total flavonoid intake, the HRs for hospital 
admissions for atherosclerotic cardiovascular disease 
lowered with increasing smoking intensity (pack-years) 
and were lowest for participants who consumed 20–40 g 
per day of alcohol (appendix p 6). We observed a lower 
risk of atherosclerotic cardiovascular disease associated 
with higher flavonoid intake in participants with normal 
weight and overweight (BMI 18·5–30), but not in those 
who were obese (BMI >30; figure 4, appendix p 6). A total 
flavonoid intake of 1000 mg per day was associated with a 
20% lower risk of atherosclerotic cardiovascular disease 
in partici pants with BMI 18·5–30 (HR 0·80, 95% CI 
Figure 3: Association between major flavonoid compound intakes (mg per day) and total hospital admissions 
for atherosclerotic cardiovascular disease
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, body-mass index, smoking status, 
social economic status (income), physical activity, and alcohol intake (model 2), and are comparing the specific level 
of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile.
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0·75–0·86) than an intake of 175 mg per day, but no lower 
risk in participants with a BMI higher than 30 (HR 0·99, 
0·87–1·14). A difference in association between men 
and women was apparent only for intakes greater than 
1000 mg per day, in which 95% CIs also widened 
substantially.
Using only validated cases, and after excluding a 
further seven participants who had a diagnosis 
of validated atherosclerotic cardiovascular disease 
(n=53 545), 3479 participants were admitted to hospital 
for any atherosclerotic cardiovascular disease, 2505 were 
admitted for myocardial infarction, 923 for ischaemic 
stroke, and 818 for peripheral artery disease. Compared 
with a total flavonoid intake of 175 mg per day (median 
intake in quintile 1), an intake of 1000 mg per day was 
associated with a 17% lower risk of atherosclerotic 
cardiovascular disease (HR 0·83, 95% CI 0·76–0·91). For 
atherosclerotic cardiovascular disease subtypes, a total 
flavonoid intake of 1000 mg per day, compared with the 
median intake in quintile 1, was associated with a non-
significant 9% lower risk of myocardial infarction (0·91, 
0·82–1·02), an 18% lower risk of ischaemic stroke (0·82, 
0·68–0·98), and a 35% lower risk of peripheral artery 
disease (0·65, 0·53–0·79; appendix p 7).
Discussion
Diet is a primary modifiable risk factor for cardiovascular 
disease.2 Therefore, dietary changes have great potential 
to affect cardiovascular disease incidence, especially in 
populations at high risk. In this prospective cohort study 
of 53 552 Danish people without atherosclerotic cardio-
vascular disease at recruitment, we found that a moderate 
intake of flavonoids was inversely associated with 
incident hospital admissions for atherosclerotic cardio-
vascular disease, with no additional benefits seen for 
intakes greater than 1000 mg per day. This inverse 
association was strongest in subpopulations prone to 
atherosclerosis including smokers and individuals who 
consumed high quantities of alcohol.
Flavonoid intake in Denmark is similar to intakes 
reported for other European countries and generally 
lower than intakes reported for the UK, because of a 
lower average consumption of tea.13 In the past few 
years, studies assessing the relationship between 
flavonoid intake and cardiovascular disease have 
focused primarily on mortality from any cardiovascular 
disease18 or coronary heart disease and ischaemic stroke, 
both indivi dually and combined.19,20 A 2017 meta-analysis 
found that total flavonoid intake was marginally, but not 
significantly, associated with a lower risk of cardio-
vascular disease mortality (relative risk 0·85, 95% CI 
0·70–1·03) for the highest versus lowest category of 
total flavonoid intake;18 similar risk estimates have been 
reported in other meta-analyses.21,22 Indeed, our previous 
study in the Danish Diet Cancer, and Health cohort 
showed that participants in the highest quintile of 
flavonoid intake had a 15% lower risk of cardiovascular 
disease mortality (HR 0·85, 95% CI 0·78–0·93) than 
that of participants in the first quintile.23 Although a 
trend for a reduced risk of cardiovascular disease 
with higher levels of flavonoid intake exists, this is 
generally non-significant after adjusting for potential 
con founders.18 In this study, we used hospital admission 
for ischaemic heart disease, ischaemic stroke, and 
peripheral artery disease as markers of atherosclerotic 
and thromboembolic cardio vascular disease rather than 
an unselective array of cardiovascular disease diagnoses. 
These events were our chosen outcomes of interest 
because in-vivo evidence suggests that flavonoids might 
impede the initiation and progress ion of atherosclerosis 
by restoring endothelial homoeo stasis and attenuating 
inflammation.7 In our study, total flavonoid intake was 
significantly associated with less hospital admissions 
for athero sclerotic cardiovascular disease after adjust-
ment for potential lifestyle and dietary confounders. 
This result might be due to our use of hospital 
admissions rather than mortality, allowing us to include 
peripheral artery disease, which is an underlying risk 
factor for cardio vascular disease mortality and a marker 
of widespread atherosclerosis, but is rarely fatal in 
itself.24 To our knowledge, one other observational study 
(n=1658) has looked at combined cardiovascular disease 
incidence, including peripheral artery disease, and 
reported an inverse association with total flavonoid 
intake when comparing the highest tertile with the 
lowest (HR 0·46, 95% CI 0·28–0·75).25 In our study, the 
inverse association between total flavonoid and athero-
sclerotic cardiovascular disease plateaued at intakes of 
approxi mately 1000 mg per day. Two cups of black tea, 
Figure 4: Stratified, multivariable-adjusted associations between total flavonoid intake and total hospital 
admissions for atherosclerotic cardiovascular disease
Multivariable-adjusted associations are stratified by baseline smoking status, alcohol intake, BMI, and sex. 
Hazard ratios are based on Cox proportional hazards models and are comparing the specific level of flavonoid 
intake (horizontal axis) with the median intake for participants in the lowest intake quintile (175 mg per day). 
All analyses were standardised for age, sex, BMI, smoking status, social economic status (income), physical activity, 
and alcohol intake (model 2), not including the stratification variable for each subgroup. BMI=body-mass index.
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100 g of blueberries, one apple, one glass of red wine, 
100 g of black beans, and 100 g of dark chocolate 
would provide more than 1000 mg of flavonoids.4 
Evidence exists that flavonoid bioactivity does not follow 
a classic linear dose–response association.20 However, 
the threshold might differ in specific subpopu lations at 
elevated cardiovascular disease risk, such as smokers 
and individuals who consume high quantities of 
alcohol.
Flavonoids have been reported to positively influence 
cardiovascular disease by acting upon common cross-
talking proteins that control the anti-inflammatory Nrf2 
pathway and the pro-inflammatory NF-Kβ pathway.7 
Additionally, after metabolism, flavonoid conjugates in 
the circulatory system can act on both endothelial cells 
and underlying smooth muscle cells, regulating vascular 
health7 We provide hypothesis-stimulating evidence that 
the inverse associations observed for flavonoid intake 
were strongest for peripheral artery disease, followed by 
ischaemic stroke and ischaemic heart disease. This might 
be due to the underlying pathology of these diseases 
and the mechanisms by which flavonoids exert their 
cardiovascular protective effects, which our results 
suggest are primarily in the peripheral arteries and 
should be investigated further.
Results from our study indicate that the inverse 
association between flavonoid intake and atherosclerotic 
cardiovascular disease was stronger in current smokers 
and individuals who consume high quantities of alcohol, 
two populations at a higher risk of atherosclerosis and 
clinical atherosclerotic cardiovascular disease than those 
who do not smoke or drink or do so in low quantities. 
Cigarette smoking is an important risk factor for 
atherosclerosis and peripheral artery disease.26 In a 
randomised controlled trial done in healthy smokers, 
supplementation with flavonoid-rich grape juice restored 
vascular function and decreased smoking-induced 
inflammatory and fibrinolytic biomarkers.27 Taken 
together, these findings provide evidence that flavonoid-
rich foods might mitigate the risk of athero sclerotic 
cardiovascular disease in smokers. The finding that the 
inverse association was stronger in individuals with high 
alcohol consumption is complex because red wine, a 
dietary source of flavonoids, is linked with cardiovascular 
health benefits.28 Drinking more than two standard 
drinks per day has been consistently associated with an 
elevated risk of cardiovascular disease by a plethora of 
purported mechanisms, including an increase in blood 
pressure, systemic atherosclerosis, and inflamma tory 
endothelial markers.29 The increasing evidence that 
flavonoids might ameliorate the detrimental effects of 
cigarette smoking and high alcohol consumption30,31 is 
supported by our study.
The weaker inverse association observed between 
flavonoid intake and atherosclerotic cardiovascular dis-
ease in participants with obesity opposes our a-priori 
hypothesis that flavonoids would be more protective in 
this subgroup, because this population is prone to higher 
levels of atherosclerosis than those of individuals with 
lower BMI. Although evidence exists that flavonoids 
affect body composition,32 individuals with obesity have a 
disparate gut microbial composition.33 This is important, 
because the gut microbiome has a crucial role in 
flavonoid metabolism and thus, in bioactivity,34 which 
might explain the weak association in this subpopulation. 
We should note the differing baseline hazards between 
obese and non-obese subpopulations, indicating that 
these findings require corroboration on an absolute 
scale. With few people with diabetes at baseline, our 
study was probably underpowered to detect a difference 
in associ ation between flavonoid intake and 
atherosclerotic cardiovascular disease in this high-risk 
population. Future research should assess if flavonoid 
intake is associated with atherosclerotic cardiovascular 
disease incidence in people with diabetes.
Our study has several strengths and some limitations. 
The large adult population followed up for 23 years, with 
a large number of events and almost no loss to follow-up, 
allowed us to examine associations in subpopulations. 
Our findings were supported, and even strengthened, 
with the validated case analysis. Because of the nature of 
the study, we were not able to infer causality or rule out 
residual or unmeasured confounding; however, the 
associations were not altered substantially by further 
adjustments. We acknowledge the limitations of 
common food-frequency questionnaires, particularly 
that not all flavonoid-rich foods (eg, berries) were 
included in the questionnaire. Because we only had 
baseline data, we acknowledge that some of these 
measures might have changed over the 23 years of 
follow-up; however, this measurement error would have 
most likely attenuated any associations. Furthermore, 
because the Danish population is more homogeneous 
than many other countries, further studies are warranted 
to determine whether similar associations exist in 
populations outside of this cohort.
In this Danish prospective cohort study, we observed 
an inverse association between flavonoid intake of up to 
1000 mg per day and hospital admissions for athero-
sclerotic cardiovascular disease, after which we detected 
no additional benefits. The strongest associations 
observed were for peripheral artery disease and for 
atherosclerotic cardio vascular disease in smokers and 
high alcohol consumers. These findings need to be 
further explored and, if replicated, might provide a novel 
means of mitigating athero sclerotic cardiovascular 
disease risk by ensuring an adequate consumption of 
flavonoid-rich foods, particularly in subpopula tions 
prone to athero sclerosis.
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